Abstract
Direct Oral Anticoagulants (DOACs) require specific dosing and monitoring to ensure safe and appropriate use. The purpose of this evaluation was to identify patient- and process-related factors that correlate with increased risk of inappropriate prescribing of DOACs. A retrospective chart review was conducted in three outpatient clinics within an academic medical center to identify patients started on DOAC therapy and evaluate the appropriateness of DOAC initiation. Data collected included patient demographics, DOAC medication initiated, dose, indication, baseline laboratory values, concomitant medications, type and specialty of prescriber, and initiation setting. Appropriateness of initial dose was assessed and data were analyzed in order to identify factors correlating with inappropriate use. One-hundred sixty-seven patients initiated on a DOAC were identified. Most patients were prescribed anticoagulation for atrial fibrillation (74.9 %) and most commonly prescribed rivaroxaban (62.9 %). An inappropriate dose was prescribed in 24 (14.4 %) patients. Female patients and patients over 75 years were more likely to be prescribed an inappropriate initial dose. Baseline evaluation of blood counts and organ function were often not performed: hemoglobin values had not been drawn within the month prior to initiation in 28.7 % of patients, serum creatinine in 22.8 %, alanine transaminase in 52.1 %, and total bilirubin in 64.1 %. Lack of baseline labs was more pronounced in patients initiated on a DOAC in the outpatient setting. Dosing and baseline lab collection for DOAC initiation were suboptimal in all settings analyzed. Targeted interventions are needed to ensure the safe and appropriate use of DOAC therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Pradaxa® (dabigatran) (2015) [package insert]. Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield
Xarelto® (rivaroxaban) (2016) [package insert]. Janssen Ortho, LLC, Gurabo
Eliquis® (apixaban) (2016) [package insert]. Bristol-Myers Squibb Company, Princeton
Savaysa™ (edoxaban) (2015) [package insert]. Daiichi Sankyo, Parsippany
Guyatt GH, Akl EA, Crowther M et al (2012) Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):7S–47S
Levy JH, Spyropoulos AC, Samama CM, Douketis J (2014) Direct oral anticoagulants: new drugs and new concepts. J Am Coll Cardiol Intv 7(12):133–1351
Kirley K, Qato DM, Kornfield R, Stafford RS, Alexander GC (2012) National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes 5(5):615–621
Luger S, Homann C, Kraft P et al (2014) Prescription frequency and predictors for the use of novel direct oral anticoagulants for secondary stroke prevention in the first year after their marketing in Europe—a multicentric evaluation. Int J Stroke 9(5):569–575
Simon J, Hawes E, Deyo Z, Shilliday BB (2015) Evaluation of prescribing and patient use of target-specific oral anticoagulants in the outpatient setting. J Clin Pharm Ther 40(5): 525–530
Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365(10):883–891
Connolly SJ, Ezekowitz MD, Yusuv S, Eikelboom J, Oldgren J et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151
Connolly SJ, Eikelboom, Joyner C, Diener HC, Hart R et al (2011) Apixaban in patients with atrial fibrillation. N Engl J Med 364:806–817
Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981092
EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, Buller HR et al (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363:2499–2510
Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H et al (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361:2342–2352
Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M et al (2013) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369:799–808
Heidbuchel H, Verhamme P, Alings M et al (2013) European Heart Rhythm Association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J 34:2094–2106
Burnett AE, Mahan CE, Vazquez SR, Oertel LB, Garcia DA, Ansel J (2016) Guidance for the practical management of direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis 41:206–232
Bright TJ, Wong A, Dhurjati R et al (2012) Effect of clinical decision-support systems: a systematic review. Ann Intern Med 157(1):29–43
Garg AX, Adhikari NK, McDonald H et al (2005) Effects of computerized clinical decision support systems on practitioner performance and patient outcomes. JAMA 293(10):1223–1238
Kaushal R, Shojania KG, Bates DW (2003) Effects of computerized physician order entry and clinical decision support systems on medication safety: a systematic review. Arch Intern Med 163(12):1409–1416
Shore S, Ho PM, Lambert-Kerzner A et al (2015) Site-level variation in and practices associated with dabigatran adherence. JAMA 313(14):1443–1450
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Howard, M., Lipshutz, A., Roess, B. et al. Identification of risk factors for inappropriate and suboptimal initiation of direct oral anticoagulants. J Thromb Thrombolysis 43, 149–156 (2017). https://doi.org/10.1007/s11239-016-1435-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11239-016-1435-3